Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

An Observational Study of the Prescribing Practices and Patient Reported Outcomes Measures in Older People with Myelodysplastic Syndrome

Angela Molga, MBBS, Michelle Wall, Dip HE (Nursing), BA (Hons), MSc, PG Cert, Rakchha Chhetri, MBBS, Amilia Wee, BSc (Hons), Deepak Singhal, MBBS, MDFRACP, FRCPA, Pratyush Giri, MBBS,FRACP,FRCPA, Timothy To, BSc, BMBS, FRACP, FAChPM, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD

Blood (2019) 134 (Supplement_1): 5426.

https://doi.org/10.1182/blood-2019-132164

Published: 2019

Journal Articles

Botanical Product Use Among Multiple Myeloma Patients in Commercial Drug Trials

Jessica K Roydhouse, PhD MPH, Vishal Bhatnagar, MD, Tara Berman, MD, Laurel A Menapace, MD, Rajiv Agarwal, Mallorie H. Fiero, PhD, Paul Kluetz, MD

Blood (2019) 134 (Supplement_1): 4769.

https://doi.org/10.1182/blood-2019-124168

Published: 2019

Journal Articles

Characteristics of "Older Old" Patients with Sickle Cell Anemia Who Survived for More Than 80 Years

Dianne Pulte, MD, Gaye Riddick-Burden, MSN, Samir K. Ballas, MD

Blood (2015) 126 (23): 4599.

https://doi.org/10.1182/blood.V126.23.4599.4599

Published: 2015

Journal Articles

Concomitant Medications and Gastrointestinal Events in Thalassemia and MDS Patients Receiving Deferasirox for Transfusional Iron Overload: Data From the EPIC Study

M Domenica Cappellini, MD, Amal El-Beshlawy, MD, John B Porter, MD, Antonis Kattamis, MD, PhD, Kerry Taylor, MD, Christian Rose, Vernon J Louw, MD, Ali El-Ali, MD, Nicolas Martin, MS, Norbert Gattermann, MD

Blood (2012) 120 (21): 5182.

https://doi.org/10.1182/blood.V120.21.5182.5182

Published: 2012

Journal Articles

Response Rate of 16% and High Incidence of Adverse Events In Placebo-Treated Patients with CD25 Assay-Positive Cutaneous T-Cell Lymphoma (CTCL): An Analysis of Patient Characteristics and Predictors of Response

Miles Prince, MD, FRACP, FRCPA, Madeleine Duvic, MD, Ann Martin, MD, Wolfram Sterry, MD, Chalid Assaf, MD, David Straus, MD

Blood (2010) 116 (21): 4158.

https://doi.org/10.1182/blood.V116.21.4158.4158

Published: 2010

Journal Articles

Management and Supportive Care Measures of Adverse Events (AEs) in Higher-Risk MDS Patients (Pts) Treated with Azacitidine (AZA).

Valeria Santini, MD, Pierre Fenaux, MD, PhD, Ghulam J Mufti, MBBS, DM, FRCP, FRCPath, Eva Hellström-Lindberg, MD, PhD, Lewis B. Silverman, MD, Alan List, MD, Steven D. Gore, MD, John F Seymour, MBBS, PhD, FRACP, Jay Backstrom, MD, MPH, David McKenzie, MS, C. L Beach, PharmD

Blood (2008) 112 (11): 1653.

https://doi.org/10.1182/blood.V112.11.1653.1653

Published: 2008

NARROW

An Observational Study of the Prescribing Practices and Patient Reported Outcomes Measures in Older People with Myelodysplastic Syndrome

Botanical Product Use Among Multiple Myeloma Patients in Commercial Drug Trials

Characteristics of "Older Old" Patients with Sickle Cell Anemia Who Survived for More Than 80 Years

Concomitant Medications and Gastrointestinal Events in Thalassemia and MDS Patients Receiving Deferasirox for Transfusional Iron Overload: Data From the EPIC Study

Response Rate of 16% and High Incidence of Adverse Events In Placebo-Treated Patients with CD25 Assay-Positive Cutaneous T-Cell Lymphoma (CTCL): An Analysis of Patient Characteristics and Predictors of Response

Management and Supportive Care Measures of Adverse Events (AEs) in Higher-Risk MDS Patients (Pts) Treated with Azacitidine (AZA).

Email alerts

ASH Publications

American Society of Hematology

An Observational Study of the Prescribing Practices and Patient Reported Outcomes Measures in Older People with Myelodysplastic Syndrome

Botanical Product Use Among Multiple Myeloma Patients in Commercial Drug Trials

Characteristics of "Older Old" Patients with Sickle Cell Anemia Who Survived for More Than 80 Years

Concomitant Medications and Gastrointestinal Events in Thalassemia and MDS Patients Receiving Deferasirox for Transfusional Iron Overload: Data From the EPIC Study

Response Rate of 16% and High Incidence of Adverse Events In Placebo-Treated Patients with CD25 Assay-Positive Cutaneous T-Cell Lymphoma (CTCL): An Analysis of Patient Characteristics and Predictors of Response

Management and Supportive Care Measures of Adverse Events (AEs) in Higher-Risk MDS Patients (Pts) Treated with Azacitidine (AZA).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only